CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
Builds on CSL Behring's promise to patients with rare and serious diseases
Gene and stem cell-based therapies complements the Company's extensive expertise in protein-based therapies
Sickle cell product candidate (CAL-H) - a strategic fit for CSL Beh... Biopharmaceuticals, Mergers & Acquisitions CSL Behring, Calimmune, Cytegrity, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Mergers and Aquisitions | Pharmaceuticals | Sickle Cell Anemia | Stem Cell Therapy | Stem Cells